{"id":"https://openalex.org/W2007276247","doi":"https://doi.org/10.1080/10543409408835079","title":"Practical modifications of the continual reassessment method for phase i cancer clinical trials","display_name":"Practical modifications of the continual reassessment method for phase i cancer clinical trials","publication_year":1994,"publication_date":"1994-01-01","ids":{"openalex":"https://openalex.org/W2007276247","doi":"https://doi.org/10.1080/10543409408835079","mag":"2007276247","pmid":"https://pubmed.ncbi.nlm.nih.gov/7951271"},"language":"en","primary_location":{"id":"doi:10.1080/10543409408835079","doi":"https://doi.org/10.1080/10543409408835079","is_oa":false,"landing_page_url":"https://doi.org/10.1080/10543409408835079","pdf_url":null,"source":{"id":"https://openalex.org/S56946555","display_name":"Journal of Biopharmaceutical Statistics","issn_l":"1054-3406","issn":["1054-3406","1520-5711"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Biopharmaceutical Statistics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2007276247"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5070178181","display_name":"Douglas E. Faries","orcid":"https://orcid.org/0000-0001-8952-7738","observed_orcids":["https://orcid.org/0000-0001-8952-7738"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Douglas Faries","raw_affiliation_strings":["a Eli Lilly & Company , Lilly Corporate Center , Indianapolis, Indiana, 46285","Eli Lilly & Company , Lilly Corporate Center , Indianapolis, Indiana, 46285"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"a Eli Lilly & Company , Lilly Corporate Center , Indianapolis, Indiana, 46285","institution_ids":["https://openalex.org/I168537998"]},{"raw_affiliation_string":"Eli Lilly & Company , Lilly Corporate Center , Indianapolis, Indiana, 46285","institution_ids":["https://openalex.org/I168537998"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5070178181"],"corresponding_institution_ids":["https://openalex.org/I168537998"],"apc_list":null,"apc_paid":null,"fwci":3.4118,"has_fulltext":false,"cited_by_count":239,"citation_normalized_percentile":{"value":0.92996892,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"4","issue":"2","first_page":"147","last_page":"164"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11798","display_name":"Optimal Experimental Design Methods","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1803","display_name":"Management Science and Operations Research"},"field":{"id":"https://openalex.org/fields/18","display_name":"Decision Sciences"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/continual-reassessment-method","display_name":"continual reassessment method","score":0.9980000257492065},{"id":"https://openalex.org/keywords/cancer-clinical-trials","display_name":"cancer clinical trials","score":0.7649999856948853},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.7129999995231628},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.675000011920929}],"concepts":[{"id":"https://openalex.org/C2777334693","wikidata":"https://www.wikidata.org/wiki/Q659446","display_name":"Maximum tolerated dose","level":3,"score":0.8112704753875732},{"id":"https://openalex.org/C96250715","wikidata":"https://www.wikidata.org/wiki/Q965330","display_name":"Estimation","level":2,"score":0.6148216128349304},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5948590636253357},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5457356572151184},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5082830786705017},{"id":"https://openalex.org/C2779974597","wikidata":"https://www.wikidata.org/wiki/Q28448986","display_name":"Clinical Practice","level":2,"score":0.4445529878139496},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.37167343497276306},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.24719825387001038},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.0918523371219635},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.06949928402900696},{"id":"https://openalex.org/C187736073","wikidata":"https://www.wikidata.org/wiki/Q2920921","display_name":"Management","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012107","descriptor_name":"Research Design","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":true},{"descriptor_ui":"D012984","descriptor_name":"Software","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017321","descriptor_name":"Clinical Trials, Phase I as Topic","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1080/10543409408835079","doi":"https://doi.org/10.1080/10543409408835079","is_oa":false,"landing_page_url":"https://doi.org/10.1080/10543409408835079","pdf_url":null,"source":{"id":"https://openalex.org/S56946555","display_name":"Journal of Biopharmaceutical Statistics","issn_l":"1054-3406","issn":["1054-3406","1520-5711"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Biopharmaceutical Statistics","raw_type":"journal-article"},{"id":"pmid:7951271","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/7951271","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of biopharmaceutical statistics","raw_type":"Journal Article"},{"id":"mag:2307034203","doi":null,"is_oa":false,"landing_page_url":"http://ci.nii.ac.jp/naid/30028378695","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9476000070571899,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":12,"referenced_works":["https://openalex.org/W627977585","https://openalex.org/W1570590815","https://openalex.org/W1612551514","https://openalex.org/W1727163805","https://openalex.org/W2005920914","https://openalex.org/W2006702541","https://openalex.org/W2032987475","https://openalex.org/W2054383376","https://openalex.org/W2076108528","https://openalex.org/W2149314588","https://openalex.org/W2167735418","https://openalex.org/W2320150582"],"related_works":["https://openalex.org/W2158740848","https://openalex.org/W2165524738","https://openalex.org/W1978972668","https://openalex.org/W291596351","https://openalex.org/W1538000603","https://openalex.org/W2078274740","https://openalex.org/W7097033897","https://openalex.org/W291055518","https://openalex.org/W4401890046","https://openalex.org/W2064122822"],"abstract_inverted_index":{"The":[0,64,91],"continual":[1],"reassessment":[2],"method":[3,98],"(1)":[4],"(CRM)":[5],"for":[6],"phase":[7],"I":[8],"cancer":[9],"trials":[10],"provides":[11],"improved":[12],"estimation":[13,71],"of":[14,59,72,79,87],"the":[15,29,34,60,73,77,85,96],"maximum":[16],"tolerated":[17],"dose":[18,25,47,89],"(MTD),":[19],"and":[20,75],"fewer":[21],"patients":[22],"receive":[23],"ineffective":[24,80],"levels":[26,48],"compared":[27],"to":[28,43],"traditionally":[30],"used":[31],"design.":[32],"However,":[33],"CRM":[35,61,92],"has":[36],"not":[37],"gained":[38],"acceptance":[39],"in":[40,99],"practice":[41],"owing":[42],"concerns":[44],"with":[45,93],"administering":[46],"that":[49,69],"are":[50,62],"too":[51],"toxic.":[52],"In":[53],"this":[54],"article,":[55],"several":[56],"conservative":[57],"modifications":[58],"introduced.":[63],"result":[65],"is":[66],"a":[67,100],"procedure":[68],"improves":[70],"MTD":[74],"decreases":[76],"use":[78,86],"doses,":[81],"without":[82],"significantly":[83],"increasing":[84],"toxic":[88],"levels.":[90],"modification":[94],"outperforms":[95],"traditional":[97],"simulation":[101],"study.":[102]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":8},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":8},{"year":2014,"cited_by_count":27},{"year":2013,"cited_by_count":10},{"year":2012,"cited_by_count":10}],"updated_date":"2026-11-14T11:04:58.165337","created_date":"2016-06-24T00:00:00"}
